These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24516925)

  • 1. [Drugs clinical trials of nonalcoholic fatty liver disease: the present and future].
    Mao YM
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):808-10. PubMed ID: 24516925
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonalcoholic steatohepatitis (NASH) drugs market.
    Cassidy S; Syed BA
    Nat Rev Drug Discov; 2016 Nov; 15(11):745-746. PubMed ID: 27807356
    [No Abstract]   [Full Text] [Related]  

  • 3. [The role of antidiabetic drugs in patients with non-alcoholic fatty liver disease].
    Yang G; Yuan L
    Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):174-7. PubMed ID: 24919223
    [No Abstract]   [Full Text] [Related]  

  • 4. The NASH drug dash.
    Chi KR
    Nat Rev Drug Discov; 2015 Jul; 14(7):447-8. PubMed ID: 26129791
    [No Abstract]   [Full Text] [Related]  

  • 5. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism.
    Rouabhia S; Milic N; Abenavoli L
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):343-9. PubMed ID: 24580044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.
    Sanyal AJ; Miller V
    Gastroenterology; 2016 Jun; 150(8):1723-7. PubMed ID: 26924092
    [No Abstract]   [Full Text] [Related]  

  • 7. Astaxanthin Improves Nonalcoholic Fatty Liver Disease in Werner Syndrome with Diabetes Mellitus.
    Takemoto M; Yamaga M; Furuichi Y; Yokote K
    J Am Geriatr Soc; 2015 Jun; 63(6):1271-3. PubMed ID: 26096415
    [No Abstract]   [Full Text] [Related]  

  • 8. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
    Musso G
    Hepatology; 2015 Jun; 61(6):2104-6. PubMed ID: 25753820
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.
    Vos MB; Dimick-Santos L; Mehta R; Omokaro SO; Taminiau J; Schabel E; Kleiner DE; Szitanyi P; Socha P; Schwimmer JB; Noviello S; Silberg DG; Torstenson R; Miller V; Lavine JE;
    Gastroenterology; 2019 Dec; 157(6):1448-1456.e1. PubMed ID: 31520612
    [No Abstract]   [Full Text] [Related]  

  • 10. End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease.
    Sanyal AJ; Neuschwander-Tetri BA; Tonascia J
    Gastroenterology; 2016 Jan; 150(1):11-3. PubMed ID: 26602217
    [No Abstract]   [Full Text] [Related]  

  • 11. [Liver diseases. Non-alcoholic fatty liver disease].
    Bernal Reyes R
    Rev Gastroenterol Mex; 2010 Aug; 75 Suppl 1():181-3. PubMed ID: 20959244
    [No Abstract]   [Full Text] [Related]  

  • 12. 20 years of leptin: leptin in common obesity and associated disorders of metabolism.
    DePaoli AM
    J Endocrinol; 2014 Oct; 223(1):T71-81. PubMed ID: 24973357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shire gobbles up Lumena and its fatty liver pills.
    Sinha G
    Nat Biotechnol; 2014 Aug; 32(8):705. PubMed ID: 25101725
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of omega-3 Fatty acids in nonalcoholic Fatty liver disease: the end of the road or a new beginning?
    Alkhouri N
    J Pediatr; 2015 Jun; 166(6):1335-7. PubMed ID: 25851650
    [No Abstract]   [Full Text] [Related]  

  • 15. The new liver epidemic.
    Garber K
    Nat Biotechnol; 2019 Mar; 37(3):209-214. PubMed ID: 30778234
    [No Abstract]   [Full Text] [Related]  

  • 16. [Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: a multiple-dose parallel controlled clinical trial].
    Tian LY; Lu LG; Tang CW; Xie Y; Luo HS; Tan SY; Pang Z; Zhang YL; Gong LB; Li YM; Chen SH; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):528-32. PubMed ID: 24074713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevalence of nonalcoholic fatty liver disease in Asia].
    Zhang W; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):801-4. PubMed ID: 24516923
    [No Abstract]   [Full Text] [Related]  

  • 18. [Fructose as a risk factor nonalcoholic fatty liver disease].
    Yi C; Li Y
    Zhonghua Gan Zang Bing Za Zhi; 2014 May; 22(5):383-5. PubMed ID: 25222975
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathological features of fatty liver disease.
    Yeh MM; Brunt EM
    Gastroenterology; 2014 Oct; 147(4):754-64. PubMed ID: 25109884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status of gut microbiota and metagenome with nonalcoholic fatty liver disease].
    Shen F; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):811-4. PubMed ID: 24516926
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.